tbuckley/cabot-search huggingface dataset:
A joint metabolic profile of plasma and tissue samples or discovering novel biomarkers in breast cancer
Authors: N. Harada, H. Tada, M. Miyashita, Y. Hamanaka, A. Sato, T. Ishida
Journal: Annals of Oncology (2018)

Background: The dysregulated tumour metabolism is one of the hallmarks of cancer. Metabolome analysis has thus been proposed as a broadly applicable tool for diagnosis and anti-cancer treatment in various cancers, such as lung, colorectal and breast cancers. Up until now, a number of metabolic biomarkers have been reported; however, there is still little application in a clinical setting due to the fact that the metabolic approach with the clinical samples has not been generally authorized. In this study, using metabolome analysis, we determined the cancer-specific metabolites and explored the applicability of the liquid biopsy for discovering the potential biomarkers of breast cancer. Methods: A total of 22 patients with breast cancer were enrolled and their metabolite levels were analyzed with CE-MS, quantitating 511 identifiable metabolites in plasma and non-cancer/cancer tissues. Samples were immediately kept in liquid nitrogen and stored at -80˚C until further tissue processing, including removal of proteins prior to CE-MS analysis. All the available metabolite data with absolute concentration were analyzed using a web-based platform, MetaboAnalyst 4.0. Results: A total of 511 known metabolites were measured; of these, 159 metabolite changes in concentration were observed in cancer tissues compared with in non-cancer tissues. In plasma samples, 67/159 metabolites significantly increased in cancer tissues. The affected metabolites were 2-hydroxyglutarate, succinate and fumarate, all of which are known as representative "oncometabolites" involved in tumorigenesis. Moreover, metabolites associated with purine synthesis and pyrimidine synthesis were also markedly upregulated. These cancer-related metabolic changes had correlation with the proliferation markers of cancer tissues. Conclusions: We identified for the first time the signature of metabolic reprograming between non-cancer and cancer tissues in breast cancer, and this metabolic shift was observed in plasma. The plasma levels of biomarkers relating to nucleic acid synthesis (purine and pyrimidine synthesis) was associated with the high proliferation status of breast cancer. Legal entity responsible for the study: Narumi Harada. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
P3.01-90 A Phase II Study Evaluating Continuation of EGFR-TKIs Beyond Progressive Disease Followed by the Addition of CDDP+PEM+Bev
Authors: S. Shoji, S. Watanabe, K. Nozaki, K. Ichikawa, R. Kondo, S. Miura, M. Okajima, T. Abe, H. Tanaka, J. Tanaka, H. Yoshizawa, H. Kagamu, T. Kikuchi
Journal: Journal of Thoracic Oncology (2018)
P1.13-03 Ensartinib Treatment Beyond Disease Progression in Stage IV ALK+ Non-Small Cell Lung Cancer
Authors: L. Horn, S. Patel, S. Waqar, G. Blumenschein, K. Harrow, A. Holzhausen, C. Liang, G. Dukart, H. Wakelee
Journal: Journal of Thoracic Oncology (2018)
CAPTEM or FOLFIRI as second-line therapy in neuroendocrine carcinomas and exploratory analysis of predictive role of PET imaging and biological markers (SENECA study)
Authors: A. Bongiovanni, S. Pusceddu, S. Leo, G. Di meglio, F. Gelsomino, F. Pucci, R. Berardi, S. Ricci, I. Lolli, F. Bergamo, D. Campana, D. Santini, S. Tamberi, D. Pastorelli, M. Cives, N. Silvestris, A. Russo, A. Buonadonna, F. Foca, T. Ibrahim
Journal: Annals of Oncology (2018)
Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292
Authors: B. Besse, V. Subbiah, A. Drilon, M. Shah, L.J. Wirth, T.M. Bauer, V. Velcheti, N. Lakhani, V. Boni, B.J. Solomon, M. Johnson, K. Park, J. Patel, M.E. Cabanillas, E. Sherman, E. Zhu, K. Gordon, K. Ebata, B. Tuch, G. Oxnard
Journal: Annals of Oncology (2018)
P2.04-17 Pre-Therapy Radiomic Features Can Distinguish Hyperprogression from Other Response Patterns to PD1/PD-L1 Inhibitors in NSCLC
Authors: P. Patil, K. Bera, P. Vaidya, M. Khorrami, P. Jain, A. Madabhushi, V. Velcheti
Journal: Journal of Thoracic Oncology (2018)
Safety and efficacy of the PD-1 inhibitor ABBV-181 in patients with advanced solid tumors: Preliminary phase I results from study M15-891
Authors: J. Powderly, P.A. Cassier, A. Cervantes, B. Gao, A. Gazzah, A. Italiano, C.-C. Lin, J.J. Luke, V. Moreno, K. Peltola, D. Rasco, A.I. Spira, M.M.E. Tanner, D. Tosi, D. Afar, S. Englert, A. Parikh, A. Reddy, G. Vosganian, A.W. Tolcher
Journal: Annals of Oncology (2018)
A phase Ib, multicenter, open-label study of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201a) combination with nivolumab for advanced HER2-expressing breast or urothelial cancer
Authors: S.A. Hurvitz, M.D. Galsky, J. Shahidi, G. Zhang, S. Raza, A. Necchi
Journal: Annals of Oncology (2018)
Avelumab (anti–PD-L1) in Japanese patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): Updated results from the phase Ib JAVELIN solid tumour JPN trial
Authors: T. Doi, S. Iwasa, K. Muro, T. Satoh, S. Hironaka, T. Esaki, T. Nishina, H. Hara, N. Machida, Y. Komatsu, Y. Shimada, S. Otsu, S. Shimizu, V. Chand, M. Watanabe
Journal: Annals of Oncology (2018)
Epidemiological and genetic data suggest the presence of an endemic form of pemphigus foliaceus in Gran Canaria, Spain
Authors: M. Grau‐Pérez, A.‐J. Gómez‐Duaso, F. Sánchez‐García, P. Rosa‐del Rey, J.‐M. González‐Martín, G. Carretero‐Hernández
Journal: British Journal of Dermatology (2018)
Clinical utility of complex multi-platform profiling in metastatic cancer patients
Authors: J. Garcia Foncillas, P.G. Aftimos, P. Barthelemy, J. Bellmunt, G. Berchem, C. Camps, R. de las Peñas, A. Finzel, J.P. Hervonen, T. Joensuu, A. Kong, J. Mackay, C. Mikropoulos, K. Mokbel, J.-L. Mouysset, T.-J. Perren, G. Guitti, J.-F. Laes
Journal: Annals of Oncology (2018)
P1.01-78 The Incidence of Brain Metastases in ROS1-Rearranged Non-Small Cell Lung Cancer at Diagnosis and Following Progression on Crizotinib
Authors: T. Patil, D. Smith, P. Bunn, D. Aisner, A. Le, M. Hancock, W. Purcell, D. Bowles, R. Camidge, R. Doebele
Journal: Journal of Thoracic Oncology (2018)
Abstract MP41: Disentangling the Effects of Aging and Menopausal Status on Cardiovascular Risk Factors
Authors: Veerle Dam, Annelien C de Kat, N. C Onland-Moret, Marinus J Eijkemans, Frank J Broekmans, Yvonne T van der Schouw
Journal: Circulation (2016)

Introduction: Menopause is thought to be associated with adverse cardiovascular disease (CVD) risk factors, in particular lipid levels, but risk factors also deteriorate because of natural aging. Hypothesis: We hypothesized that menopausal status has an effect on CVD risk factors independent of age. Methods: We used data from LifeLines, a population-based prospective cohort study in the Netherlands. Female participants aged 18-65 years old were divided into groups according to menopausal status: pre- (n=42,987), peri- (n=14,266), natural post- (n=11,175) and surgically postmenopausal (n=5,234). To assess the effect of menopausal status, we compared mean risk factor levels by menopausal status, within one-year age strata, using linear regression. We assessed the effect of age per year on mean CVD risk factor level, within each menopausal status, using linear regression and splines to check for non-linearity. Models were adjusted for oral contraceptive use, smoking status and body mass index (BMI). Results: As expected, systolic and diastolic blood pressure (SBP, DBP), and low-density lipoprotein cholesterol (LDL-c) levels increased with age for women in each menopausal status; but high-density lipoprotein cholesterol (HDL-c) also increased. The increase of SBP with age seemed more pronounced in premenopausal women (Figure 1). SBP levels were significantly higher in premenopausal women compared to peri-, natural post- and surgically postmenopausal women. Natural and surgically postmenopausal women had significantly higher LDL-c levels compared to premenopausal women. HDL-c levels were highest in natural postmenopausal women and lowest in surgically postmenopausal women. BMI increased slightly with age, and roughly stabilized from age 45. BMI was lowest in postmenopausal women, higher for pre- and perimenopausal women and highest for surgical postmenopausal women. Conclusions: This study provides evidence for an effect of menopausal status on CVD risk factors, independent of biological aging.
Radiotherapy induces responses of lung cancer to CTLA-4 blockade
Authors: Silvia C. Formenti, Nils-Petter Rudqvist, Encouse Golden, Benjamin Cooper, Erik Wennerberg, Claire Lhuillier, Claire Vanpouille-Box, Kent Friedman, Lucas Ferrari de Andrade, Kai W. Wucherpfennig, Adriana Heguy, Naoko Imai, Sacha Gnjatic, Ryan O. Emerson, Xi Kathy Zhou, Tuo Zhang, Abraham Chachoua, Sandra Demaria
Journal: Nature Medicine (2018)
P2.01-91 Treatment Patterns in Patients with Stage IIIB-IV NSCLC in Clinical Practice: Retrospective Analysis of a UK Trust Database
Authors: M. Snee, S. Cheeseman, M. Thompson, L. Lacoin, W. Sopwith, C. Chaib, M. Daumont, J. Penrod, J. O'Donnell, G. Hall
Journal: Journal of Thoracic Oncology (2018)
KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
Authors: B. Burtness, K.J. Harrington, R. Greil, D. Soulières, M. Tahara, G. De Castro, A. Psyrri, N. Baste Rotllan, P.C. Neupane, Å Bratland, T. Fuereder, B.G.M. Hughes, R. Mesia, N. Ngamphaiboon, T. Rordorf, W.Z. Wan Ishak, A. Roy, J. Cheng, F. Jin, D. Rischin
Journal: Annals of Oncology (2018)
P2.06-10 Combination Chemotherapy with Cisplatin, Pemetrexed, and Nivolumab for Malignant Pleural Mesothelioma: A Trial in Progress
Authors: N. Fujimoto, K. Aoe, T. Kozuki, I. Oze, K. Kato, T. Kishimoto, K. Hotta
Journal: Journal of Thoracic Oncology (2018)
P2.16-32 Survival Implications and Factors Associated with the Anatomic Level of Incomplete Non-Small-Cell Lung Cancer (NSCLC) Resection
Authors: Y. Lee, M. Smeltzer, M. Ray, N. Faris, C. Fehnel, C. Houston-Harris, O. Akinbobola, P. Ojeabulu, E. Owen, R. Eubanks, H. Dox, D. Talton, H. Wiggins, B. Wolf, P. Levy, E. Robbins, R. Osarogiagbon
Journal: Journal of Thoracic Oncology (2018)
Neutrophil-lymphocyte ratio (NLR) as an important prognostic factor for paclitaxel as a second line chemotherapy in advanced gastric cancer (AGC): Results from phase III DREAM study
Authors: M.-H. Ryu, J.H. Kim, S.C. Oh, S. Park, J.G. Kim, J.W. Kim, S.-H. Cho, K.-E. Yoon, Y.-K. Kang
Journal: Annals of Oncology (2018)
Phase I/II study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody BGB-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors
Authors: J. Desai, M. Voskoboynik, B. Markman, J. Hou, D. Zeng, T. Meniawy
Journal: Annals of Oncology (2018)
An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial)
Authors: C.R. Mehta, L. Liu, C. Theuer
Journal: Annals of Oncology (2018)

BackgroundMajor challenges in clinical trials of ultra-orphan oncology diseases include limited patient availability and paucity of reliable prior data for estimating the treatment effect and, therefore, determining optimal sample size. Angiosarcoma (AS), a particularly aggressive form of soft tissue sarcoma with an incidence of about 2000 cases per year in the United States and Europe is poorly addressed by current systemic therapies. Pazopanib, an inhibitor of vascular endothelial growth factor receptor (VEGFR) is approved for the treatment of AS, with modest benefit. TRC105 (carotuximab) is a monoclonal antibody to endoglin, an essential angiogenic target highly expressed on proliferating endothelium and both tumor vessels and tumor cells in AS, that has the potential to complement VEGFR tyrosine kinase inhibitors. In a phase I/II study of soft tissue sarcoma, TRC105 combined safely with pazopanib and the combination demonstrated durable complete responses and encouraging progression-free survival (PFS). In addition, there was a suggestion of superior benefit in patients with cutaneous lesions versus those with the non-cutaneous lesions.Patients and methodsThis article describes the design of a recently initiated phase III trial of TRC105 And Pazopanib versus Pazopanib alone in patients with advanced AngioSarcoma (TAPPAS trial). Given the ultra-orphan status of the disease and the paucity of reliable prior data on PFS or overall survival (end points required for regulatory approval as a pivotal trial), an adaptive design incorporating population enrichment and sample size re-estimation was implemented. The design incorporated regulatory input from the Food and Drug Administration (FDA) and European Medicines Agency and proceeded following special protocol assessment designation by the FDA.ConclusionsIt is shown that the benefit of the adaptive design as compared with a conventional single-look design arises from the learning and subsequent improvements in power that occur after an unblinded analysis of interim data.Registered on Clinicaltrials.govNCT02979899.
Abstract 16117: Sildenafil Reduces Pulmonary Vascular Resistance in Patients With Single Ventricular Physiology
Authors: Hiroki Mori, Mikiko Shimizu, Tetsuko Ishii, Kei Inai, Tokuko Shinohara, In-Sam Park, Hiroyuki Yamagishi, Shirou Ishikawa, Makoto Nakamura, Satoshi Yasukochi, Tsutomu Saji, Toshio Nakanishi
Journal: Circulation (2013)

Background: In patients with single ventricular physiology, risk of Fontan operation increases with higher pulmonary vascular resistance (PVR). Furthermore, in patients after Fontan operation, even...
Efficacy of racotumomab or nimotuzumab vs docetaxel as second-line therapy for advanced non-small cell lung cancer patients
Authors: M. Hernandez, E. Neninger, E. Santiesteban, K. Camacho, N. Hernandez, R. Amador, S. Acosta, Y. Gonzalez, Y. Jimenez, M. Corella, R.A. Ortiz, L. Bello, A. Calana, G. Pichs, M. Cala, Y. Flores, C. Viada, M. Robaina, T. Crombet
Journal: Annals of Oncology (2018)
MA13.09 Electromagnetic Navigation Bronchoscopy as an Integrated Approach to Aid in Diagnosis and Treatment of Pulmonary Lesions
Authors: S. Khandhar, S. Murgu, K. Hogarth, W. Krimsky, J. Flandes, O. Rickman, M. Wahidi, E. Sztejman, P. Linden, S. Benzaquen, S. Bansal, E. Folch
Journal: Journal of Thoracic Oncology (2018)
Monitoring hepatitis E virus fecal shedding to optimize ribavirin treatment duration in chronically infected transplant patients
Authors: Olivier Marion, Sébastien Lhomme, Arnaud Del Bello, Florence Abravanel, Laure Esposito, Anne Laure Hébral, Laurence Lavayssière, Olivier Cointault, David Ribes, Jacques Izopet, Nassim Kamar
Journal: Journal of Hepatology (2018)
MA01.10 Toxicity and Local Control in “Ultra-Central” Lung Tumors Treated With SBRT or High-Dose Hypofractionated RT
Authors: C. Wang, B. Sidiqi, E. Yorke, D. Mcknight, R. Dick-Godfrey, D. Torres, D. Gelblum, A. Rimner, A. Wu
Journal: Journal of Thoracic Oncology (2018)
Treatment pattern and clinical outcomes of patients with locally advanced and metastatic melanoma in a real-world setting in China
Authors: C. Cui, X. Yan, S. Liu, A. Deitz, L. Si, Z. Chi, X. Sheng, B. Lian, J. Li, J. Ge, X. Wang, L. Mao, B. Tang, L. Zhou, X. Bai, S. Li, B. Li, H. Wu, J. Guo
Journal: Annals of Oncology (2018)
Lymph nodes go with the flow
Authors: Rafael S. Czepielewski, Gwendalyn J. Randolph
Journal: The Journal of Experimental Medicine (2018)

In this issue, Bovay et al. (https://doi.org/10.1084/jem.20180217) invoke a compelling model of interplay between the venous and lymphatic vasculature in regulating the developmental genesis and early expansion of LNs. This work supports an emerging model that lymph–venous crosstalk supports LN functionality at all stages.
P2.13-33 A Case Report of Exceptional Clinical Response to MEK Inhibition in a Patient with NRAS Mutation Positive NSCLC
Authors: M. Krebs, D. Graham, M. Ayub, J. Dransfield, H. Frost, S. Aruketty, B. Kilerci, A. Wallace, R. Kamboj, D. Bakhle, V. Palle, S. Sharma, N. Maharaj, R. Kumawat, M. Bhonde, K. Frese, C. Dive, D. Rothwell, G. Brady
Journal: Journal of Thoracic Oncology (2018)
Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer
Authors: D. Harada, A. Hata, C. Okuda, R. Kaji, Y. Masuda, Y. Takechi, T. Kozuki, N. Nogami, N. Katakami
Journal: Annals of Oncology (2018)
P1.13-42 Activity of Novel HER2 Inhibitor, Poziotinib, for HER2 Exon 20 Mutations in Lung Cancer and Mechanism of Acquired Resistance
Authors: T. Koga, Y. Kobayashi, K. Tomizawa, Y. Sesumi, T. Fujino, M. Nishino, S. Ohara, M. Chiba, M. Shimoji, K. Suda, T. Takemoto, T. Mitsudomi
Journal: Journal of Thoracic Oncology (2018)
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Authors: Rodabe N. Amaria, Sangeetha M. Reddy, Hussein A. Tawbi, Michael A. Davies, Merrick I. Ross, Isabella C. Glitza, Janice N. Cormier, Carol Lewis, Wen-Jen Hwu, Ehab Hanna, Adi Diab, Michael K. Wong, Richard Royal, Neil Gross, Randal Weber, Stephen Y. Lai, Richard Ehlers, Jorge Blando, Denái R. Milton, Scott Woodman, Robin Kageyama, Daniel K. Wells, Patrick Hwu, Sapna P. Patel, Anthony Lucci, Amy Hessel, Jeffrey E. Lee, Jeffrey Gershenwald, Lauren Simpson, Elizabeth M. Burton, Liberty Posada, Lauren Haydu, Linghua Wang, Shaojun Zhang, Alexander J. Lazar, Courtney W. Hudgens, Vancheswaran Gopalakrishnan, Alexandre Reuben, Miles C. Andrews, Christine N. Spencer, Victor Prieto, Padmanee Sharma, James Allison, Michael T. Tetzlaff, Jennifer A. Wargo
Journal: Nature Medicine (2018)
Elderly patients with locally advanced head and neck squamous cell carcinoma treated with NBTXR3 nanoparticles activated by radiotherapy: A phase I trial
Authors: C. Le Tourneau, V. Calugaru, V. Moreno, X. Mirabel, B. Dodger, E. Calvo, T. Jouffroy, J. Rodriguez, A. Chilles, M. Yemi, C. Hoffmann
Journal: Annals of Oncology (2018)
MA27.01 Establishment of PDX From Tumors Characterized by EGFR Mutations or ALK Fusion Genes from Resections, Biopsies and Pleural Fluids
Authors: S. Martins-Filho, M. Cabanero, N. Pham, E. Stewart, D. Ravi, D. Patel, J. Mcconnell, A. Grindlay, F. Allison, M. Li, F. Shepherd, M. Tsao, K. Yasufuku, G. Liu
Journal: Journal of Thoracic Oncology (2018)
DNA damaging agents and immunotherapy in NSCLC: Is there a STING in the tale?
Authors: C.M. Della Corte, K. Ramkumar, T. Sen, P. Tong, D.L. Gibbons, J.V. Heymach, J. Wang, Y.-H. Fan, R. Cardnell, L. Byers
Journal: Annals of Oncology (2018)
Glypican‐3‐Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma
Authors: Ying Fu, Daniel J. Urban, Roger R. Nani, Yi‐Fan Zhang, Nan Li, Haiying Fu, Hamzah Shah, Alexander P. Gorka, Rajarshi Guha, Lu Chen, Matthew D. Hall, Martin J. Schnermann, Mitchell Ho
Journal: Hepatology (2018)

Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death in the world. Therapeutic outcomes of HCC remain unsatisfactory, and novel treatments are urgently needed. GPC3 (glypican-3) is an emerging target for HCC, given the findings that 1) GPC3 is highly expressed in more than 70% of HCC; (2) elevated GPC3 expression is linked with poor HCC prognosis; and (3) GPC3-specific therapeutics, including immunotoxin, bispecific antibody and chimeric antigen receptor T cells. have shown promising results. Here, we postulate that GPC3 is a potential target of antibody-drug conjugates (ADCs) for treating liver cancer. To determine the payload for ADCs against liver cancer, we screened three large drug libraries (> 9,000 compounds) against HCC cell lines and found that the most potent drugs are DNA-damaging agents. Duocarmycin SA and pyrrolobenzodiazepine dimer were chosen as the payloads to construct two GPC3-specific ADCs: hYP7-DC and hYP7-PC. Both ADCs showed potency at picomolar concentrations against a panel of GPC3-positive cancer cell lines, but not GPC3 negative cell lines. To improve potency, we investigated the synergetic effect of hYP7-DC with approved drugs. Gemcitabine showed a synergetic effect with hYP7-DC in vitro and in vivo. Furthermore, single treatment of hYP7-PC induced tumor regression in multiple mouse models. Conclusion: We provide an example of an ADC targeting GPC3, suggesting a strategy for liver cancer therapy.
P3.01-39 Analysis of Acquired EGFR T790M Mutation in Patients with Non-Small Cell Lung Cancer Who Received Icotinib Progress
Authors: R. Huang, C. Xu, W. Wang, J. Li, C. He, Y. Zhu, W. Zhuang, Z. Huang, Y. Chen, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2018)
Relationship between change in α-fetoprotein (AFP) and patient (pt) survival in hepatocellular carcinoma (HCC): A real-world electronic medical records (EMR) database study
Authors: L.M. Hess, Z.L. Cui, T. Sugihara, Y. Fang, A. Girvan, P.B. Abada
Journal: Annals of Oncology (2018)
P2.16-27 Indocyanine Green Virtual Assisted Lung Mapping (ICG-VAL-MAP): Anyone Can Perform a Visible Preoperative Marking Successfully
Authors: T. Chen-Yoshikawa, D. Nakajima, M. Hamaji, A. Ohsumi, T. Menju, T. Sato, M. Sonobe, H. Date
Journal: Journal of Thoracic Oncology (2018)
Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC
Authors: C. Zhou, Y. Lu, S.-W. Kim, T. Reungwetwattana, J. Zhou, Y. Zhang, J. He, J.-J. Yang, Y. Cheng, S.H. Lee, L. Bu, T. Xu, L. Yang, C. Wang, P.N. Morcos, E. Mitry, T. Liu, L. Zhang
Journal: Annals of Oncology (2018)
Serum assessment of non-adherence to adjuvant endocrine therapy (ET) among premenopausal patients in the prospective multicenter CANTO cohort
Authors: B. Pistilli, A. Paci, S. Michiels, A. Ferreira, V. Poinsignon, P.H. Cottu, F. Lerebours, C. Coutant, A. Lesur, O. Tredan, P. Soulie, L. Vanlemmens, C. Jouannaud, C. Levy, S. Everhard, P. Arveux, A.H. Partridge, S. Delaloge, F. André, I. Vaz-Luis
Journal: Annals of Oncology (2018)
Treatment patterns in elderly patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results from an EORTC led survey
Authors: S. Oosting, I. Desideri, D. Staelens, C. Caballero, S. Tribius, C. Simon, S. Singer, V. Gregoire, C. Fortpied, A. Luciani
Journal: Annals of Oncology (2018)
Cancer care-related social media (SM) and internet usage differences between adolescents and young adults (AYA), adults and elderly patients with cancer
Authors: L. Eng, J. Bender, K. Hueniken, S. Kassirian, D. Yang, L. Mitchell, C.B. Paulo, A. Magony, E.C. Smith, M. Liang, M.C. Brown, W. Xu, S.M.H. Alibhai, G. Liu, A. Gupta
Journal: Annals of Oncology (2018)
P2.04-08 Platinum-Based Chemotherapy is Associated with Altered PD-L1 Expression in Lung Cancer
Authors: J. Moldvay, L. Rojkó, V. Téglási, K. Fábián, O. Pipek, A. Vágvölgyi, L. Agócs, J. Fillinger, Z. Kajdácsi, J. Tímár, B. Döme, Z. Szállási, L. Reiniger
Journal: Journal of Thoracic Oncology (2018)
Pregnancies after breast cancer: Is there a real need for fertility preservation? Results from the ARTEMIS cohort of 60 young patients
Authors: J. Martin-Babau, F. Toudic-Emily, A.-H. Boivin, P. Burban-Provost, B. Vie, P.-L. Etienne, B. Lamezec, E. Le Fur, A. Vincent, D. Besson, A.-C. Hardy-Bessard
Journal: Annals of Oncology (2018)
Longitudinal assessment of multiplex patient-specific ctDNA biomarkers in bladder cancer for diagnosis, surveillance and recurrence
Authors: K. Birkenkamp-Demtröder, E. Christensen, H. Sethi, S. Sharma, H.-T. Wu, A. Taber, M. Agerbæk, R. Swenerton, R. Salari, D. Hafez, I. Nordentoft, P. Lamy, R. Srinivasan, M. Balcioglu, S. Navarro, Z. Assaf, B. Zimmermann, J. Lin, J. Bjerggaard Jensen, L. Dyrskjøt
Journal: Annals of Oncology (2018)
Benefit from subsequent conventional cytotoxic chemotherapy (CTx) to immunotherapy (IT) in patients (pts) with gynaecological malignancies (GM)
Authors: F.J. Ros Montañá, V. Rodriguez Freixinos, L. Fariñas Madrid, F. Amair Pinedo, F. Ruiz-Pace, E. Garralda, R. Dienstmann, A. Oaknin
Journal: Annals of Oncology (2018)